BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...

Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal in the space of a week. BMS is ...

Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs. The all-cash deal is mainly about MyoKardia’s ...

Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain. However, valuation metrics can be misleading ...

Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for ...

Bristol Myers Squibb (NYSE: BMY) today reported first quarter 2026 financial results. Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed first quarter 2026 ...

After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...